Current share price for ALA : $0.054 0.001 (1.89%)+
Arovella Therapeutics Limited (ALA, formerly Suda Pharmaceuticals Ltd) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours.
| ASX Code | ALA |
| Website | http://www.arovella.com |
| Industry/Sector | Pharmaceuticals |
| Market Cap ($M) | 65 |
| ALA Share Price | $0.054 |
| Day High | $0.054 |
| Day Low | $0.053 |
| Last Close | $0.053 |
| ALA Share Price Movement | $0.00 ( 1.89% ) |
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Arovella Therapeutics Limited (ALA) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026A | -$6.92 | -$0.60 | -14.70% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$7.51 | -$0.70 | -26.90% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$8.75 | -$0.90 | -23.10% | 0.00 | 0.00 | 0.00% | 0.0% |
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | ||
| Arovella Therapeutics Limited (ALA) | $68M | -0.1471 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Clarity Pharmaceuticals Ltd (CU6) | $787M | 0.4454 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Neuren Pharmaceuticals Limited (NEU) | $2,613M | -0.7857 | 0.2462 | 0.9655 | 88.5690 | 71.0690 | 36.1579 | 0.00% | 1.60% | 1.89% |
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 4.53 | 0.00 |
| Market | 0.33 | 13.80 | 1.17 | 0.79 |
| Sector | 0.68 | 30.70 | 2.70 | 2.03 |
| Name | Position | Start Date |
|---|---|---|
| Mr Mark P Diamond | Non-Executive Director | 28 Apr 2026 |
| Dr Michael S Perry | Non-Executive Director | 28 Apr 2026 |
| Dr Michael Joseph Thurn | Non-Executive Director | 28 Apr 2026 |
| Mr David John Williams | Non-Executive Director, Non-Executive Chairman | 28 Apr 2026 |
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 9 Jun 2026 | WILLIAMS, David | Buy | Indirect Shares | 200,000 | $0.067 | $13,400.000 |
| 12 Nov 2025 | BARTON, Debora | Exercise | Options | 1,013,333 | $0.052 | $52,693.316 |
| 13 Oct 2025 | BAKER, Michael | Exercise | Options | 1,617,021 | $0.075 | $121,276.575 |
See all changes in directors' interest & trades for Arovella Therapeutics Limited (ALA) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
| Name | Position |
|---|---|
| Nicole Louise van der Weerden | Acting Chief Executive Officer |
| Lachie Mallia | Chief Financial Officer,Company Secretary |
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Arovella Therapeutics Limited (ALA). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 0 (0%) | n/a |
| Date | Event |
|---|---|
| 19 August 2027 | Report (Annual) |
| 19 August 2027 | Report (Prelim) |
| 18 February 2027 | Report (Interim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.